Aripiprazole for agitation in a 13-year-old girl with neuroleptic malignant syndrome.
Neuroleptic Malignant Syndrome (NMS) rarely results from atypical antipsychotic therapy. To date, no information is available on the incidence of NMS with aripiprazole, a newer neuroleptic. To examine the results of a trial of aripiprazole administered to a 13-year-old Mexican-American girl during the course of NMS. Vital signs and laboratory values obtained before and during the aripiprazole trial were compared. Aripiprazole administration resulted in a mild increase in tachycardia and brief worsening of serum creatinine kinase level, but did not significantly affect temperature, respiratory rate, or blood pressure. In this adolescent with NMS, aripiprazole treatment was associated with a mild worsening of symptoms.